Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Clonal hematopoiesis and risk of mortality after incident ischemic stroke: The reasons for geographic and racial differences in stroke Study

Radhika Gangaraju, Yanjun Chen, Alexander Bick et al. Nov 03, 2025 pp. 4941-4941 10.1182/blood-2025-4941

Abstract Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk of stroke and all-cause m...

Assessing bone marrow biopsy utility in patients with unexplained cytopenias

Mariam Mostafa, Hassan Saeed, Kavya Balusu et al. Nov 03, 2025 pp. 2612-2612 10.1182/blood-2025-2612

Abstract Background : In patients with cytopenias not readily explained by non-invasive tests (unexplained cytopenias), bone marrow biopsies...

Efficacy of thiotepa-containing conditioning regimens and mucositis burden in allogeneic HSCT for relapsed/refractory acute leukemia with extramedullary disease

Minglu Li, Weijie Zhang, Yixin Yang et al. Nov 03, 2025 pp. 4192-4192 10.1182/blood-2025-4192

Abstract Background: Patients with relapsed/refractory acute leukemia (R/R AL) and extramedullary disease (EMD) exhibit significantly inferi...

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Franck Morschhauser, David Qualls, Jennifer Lue et al. Nov 03, 2025 pp. 480-480 10.1182/blood-2025-480

Abstract Introduction Approximately 20–50% of patients (pts) with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) experien...

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Kate Kroeger et al. Nov 03, 2025 pp. 5276-5276 10.1182/blood-2025-5276

Abstract Introduction: Mutated TP53 has recently been incorporated into both the ICC and WHO classifications for AML and MDS due to its asso...

TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends

Hasan Abuamsha, Emily Zabor, Moath Albliwi et al. Nov 03, 2025 pp. 5168-5168 10.1182/blood-2025-5168

Abstract Background TP53 mutations (TP53-mt) are strongly associated with poor outcomes in acute myeloid leukemia (AML)....

Estimating the burden of undiagnosed CMML: Prevalence by phenotype and cytopenia stratification in NHANES

Arjun Syal, Dahniel Sastow, Douglas Tremblay Nov 03, 2025 pp. 8205-8205 10.1182/blood-2025-8205

Abstract Background: Chronic myelomonocytic leukemia (CMML) is a rare clonal myeloid neoplasm defined by persistent monocytosis, cytopenias,...

Refractory anemia with ring sideroblasts: Epidemiological survival trends and implications in a SEER population-based study

Ahmad Abed, Berkha Rani, Sai Abhishek Narra et al. Nov 03, 2025 pp. 7382-7382 10.1182/blood-2025-7382

Abstract Introduction: Refractory Anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) subtype defined by anemia, dysery...

Trends in comorbid mortality from disseminated intravascular coagulation and sepsis in United States adults: A population-based analysis using CDC wonder database

Ahmad Qaisar, Dua Azim, Muhammad Ans Nov 03, 2025 pp. 8000-8000 10.1182/blood-2025-8000

Abstract Introduction: Disseminated intravascular coagulation (DIC) and sepsis are both associated with high morbidity and mortality in the...

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Anne Huynh, Romain Buono, Edouard Forcade et al. Nov 03, 2025 pp. 4297-4297 10.1182/blood-2025-4297

Abstract Background The ferritin level appears to be a good biomarker of iron overload in patients who underwent allogeneic hematopoietic st...

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients

Fabian Beier, Edgar Jost, Dirk-Jan Eikema et al. Nov 03, 2025 pp. 3192-3192 10.1182/blood-2025-3192

Abstract Introduction: Rabbit anti-thymocyte globulin (ATG) is a key component of conditioning regimens for patients with aplastic anemia (AA...

Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients

Luke Li, Changtai Tian, Mina Zheng et al. Nov 03, 2025 pp. 7205-7205 10.1182/blood-2025-7205

Abstract Introduction: R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) remains a frontl...

Hemodilution assessment for high-sensitivity flow cytometric measurable residual disease evaluation in pediatric B-cell acute lymphoblastic leukemia

Prashant Tembhare, Jagruti Patil, Amruta Acharya et al. Nov 03, 2025 pp. 1596-1596 10.1182/blood-2025-1596

Abstract Background: Accurate assessment of measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL) is critical for...

Trial-level meta-analysis of minimal residual disease and progression-free survival in follicular lymphoma

Vedran Radojcic, Qing Xu, Helen He Nov 03, 2025 pp. 7104-7104 10.1182/blood-2025-7104

Abstract Background: Follicular lymphoma (FL) is an indolent but incurable B-cell lymphoma. Frontline therapy for FL induces remission in la...

Music-based interventions for sickle cell disease: A systematic review of evidence on pain, mental health, and quality of life

Carlos Chiniros, John Patena, Subomi Ige et al. Nov 03, 2025 pp. 7890-7890 10.1182/blood-2025-7890

Abstract Background: Sickle Cell Disease (SCD) is the most common inherited genetic blood disorder. Over 8 million people live with SCD glob...

Efficacy and safety of clia plus venetoclax as salvage therapy for relapsed or refractory Acute Myeloid Leukemia

Sarah Sertich, Brent Harris, Yanal Alnimer et al. Nov 03, 2025 pp. 3454-3454 10.1182/blood-2025-3454

Abstract Background: Relapsed or refractory acute myeloid leukemia (R/R AML) carries poor outcomes, with standard salvage regimens yielding c...

Treatment intensity in older adults with AML: Impact of age and induction regimen on remission and survival outcomes

Yzen Almarrawi, Swathi Gopishetty, Lavi Singh et al. Nov 03, 2025 pp. 6907-6907 10.1182/blood-2025-6907

Abstract Background: Treatment decisions in older adults with acute myeloid leukemia (AML) must balance disease biology...

Patients with burkitt's lymphoma have a better survival probability if treated in an academic cancer program

Carolina Velez-Mejia, Ysaith Orellana Ascencio, Laura Reyes-Uribe et al. Nov 03, 2025 pp. 6311-6311 10.1182/blood-2025-6311

Abstract Background: Burkitt lymphoma (BL) is a highly aggressive B-cell neoplasm that can be treated with curative intent using combination...

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Douglas Tremblay, Li Chen, Zhuoxin Sun et al. Nov 03, 2025 pp. 871-871 10.1182/blood-2025-871

Abstract Introduction Nadir bone marrow biopsies (BM Bx) are routinely performed around day 14 to assess early response to AML intensive ind...

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

Adam Suleman, Kim Roos, Yidi Jiang et al. Nov 03, 2025 pp. 1814-1814 10.1182/blood-2025-1814

Abstract Background: The optimal treatment of treatment naïve (TN) Waldenström's macroglobulinaemia (WM) has not yet been defined. Recently...

Facility-level differences in treatment and outcomes for intravascular large B-cell lymphoma: A national cancer database analysis

Eleftheria Atalla, Ysaith Orellana Ascencio, Carolina Velez-Mejia et al. Nov 03, 2025 pp. 1884-1884 10.1182/blood-2025-1884

Abstract Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive subtype of extranodal diffuse large B-cell lympho...

Race does not impact chimeric antigen receptor T-cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma

Anisha Rajavel, Sushmitha Nanja Reddy, Saumya Karne et al. Nov 03, 2025 pp. 6327-6327 10.1182/blood-2025-6327

Abstract Introduction: Chimeric antigen receptor T (CAR-T) cell therapy has traditionally been administered in the inpatient (inpt) setting....

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Tae Min Kim, Jing-Zhou Hou, Sameh Gaballa et al. Nov 03, 2025 pp. 5514-5514 10.1182/blood-2025-5514

Abstract Introduction: Surovatamig (formerly AZD0486) is a novel, IgG4 fully human CD19xCD3 bispecific TCE that is being evaluated in an ong...

Reduced chronic graft versus host disease after allogeneic HSCT with cryopreserved peripheral blood stem cell grafts: A CIBMTR analysis

Alexandria Maurer, Tao Wang, Zachariah Defilipp et al. Nov 03, 2025 pp. 933-933 10.1182/blood-2025-933

Abstract During the COVID-19 pandemic, cryopreservation (cryo) of unrelated donor peripheral blood stem cells (PBSC) for allogeneic hematopo...

Increased FXII activation in endovascular treated stroke patients on periprocedural antithrombotic treatment

Angelique Ceulemans, Aarazo Barakzie, Moniek de Maat et al. Nov 03, 2025 pp. 1358-1358 10.1182/blood-2025-1358

Abstract Endovascular treatment (EVT) for large vessel occlusion in acute ischemic stroke patients (AIS) improves reperfusion rates, yet a c...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page